Frontiers in Pediatrics (Mar 2022)

Eastern India Collaboration on Multisystem Inflammatory Syndrome in Children (EICOMISC): A Multicenter Observational Study of 134 Cases

  • Snehamayee Nayak,
  • Prakash Chandra Panda,
  • Basudev Biswal,
  • Sunil Kumar Agarwalla,
  • Amit Kumar Satapathy,
  • Pradeep Kumar Jena,
  • Krishna Mohan Gulla,
  • Debasmita Rath,
  • Anuspandana Mahapatra,
  • Pravakar Mishra,
  • Debashree Priyadarshini,
  • Samarendra Mahapatro,
  • Saurav Nayak,
  • Rashmi Ranjan Das,
  • EICOMISC Study Group,
  • Majhi Subash Chandra Kumar,
  • Meher Sitanshu,
  • Poddar Chandrakant,
  • Sahoo Jyotiprakash,
  • Mohanty Martina,
  • Padhy Satya Brata,
  • Nayak Bijan Kumar,
  • Dash Shovendra Kumar,
  • Meher Soumya Ranjan,
  • Panigrahi Pranab Kumar,
  • Srikanth

DOI
https://doi.org/10.3389/fped.2022.834039
Journal volume & issue
Vol. 10

Abstract

Read online

BackgroundFew single center studies from resource-poor settings have reported about the epidemiology, clinical feature and outcome of multisystem inflammatory syndrome in children (MIS-C). However, larger data from multi-center studies on the same is lacking including from Indian setting.MethodsThis retrospective collaborative study constituted of data collected on MIS-C from five tertiary care teaching hospitals from Eastern India. Children ≤ 15 years of age with MIS-C as per the WHO criteria were included. Primary outcome was mortality.ResultsA total of 134 MIS-C cases were included (median age, 84 months; males constituted 66.7%). Fever was a universal finding. Rash was present in 40%, and conjunctivitis in 71% cases. Gastro-intestinal and respiratory symptoms were observed in 50.7% and 39.6% cases, respectively. Co-morbidity was present in 23.9% cases. Shock at admission was noted in 35%, and 27.38% required mechanical ventilation. Fifteen (11.2%) children died. The coronary abnormalities got normalized during follow-up in all except in one child. Initial choice of immunomodulation had no effect on the outcomes. Presence of underlying co-morbidity, lymphopenia, thrombocytosis, hyponatremia, increased LDH (>300 U/L), and hypoalbuminemia were the factors significantly associated an increased mortality.ConclusionsMIS-C has myriad of manifestations. Underlying co-morbidity, lymphopenia, thrombocytosis, hyponatremia, increased LDH (>300 U/L), and hypoalbuminemia were associated with an increased mortality. No difference in outcome was noted with either steroid or IVIg or both. Coronary artery abnormalities resolved in nearly all cases.

Keywords